Genetic polymorphisms in dopamine- and serotonin-related genes and treatment responses to risperidone and perospirone

Psychiatry Investigation

Volumn 6, Issue 3, 2009, Pages 222-225

  Tsutsumi, Atsushi ^a   Kanazawa, Tetsufumi ^a   Kikuyama, Hiroki ^a   Okugawa, Gaku ^b   Uenishi, Hiroyuki ^e   Miyamoto, Toshio ^d   Matsumoto, Naoki ^c   Koh, Jun ^a   Shinosaki, Kazuhiro ^c   Kishimoto, Toshifumi ^d   Yoneda, Hiroshi ^a   Kinoshita, Toshihiko ^b  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d NARA MEDICAL UNIVERSITY   (Japan)

^e KANSAI UNIVERSITY   (Japan)

Author keywords

Clinical efficacy; Perospirone; Pharmacogenetic study; Polymorphism; Risperidone

Indexed keywords

DOPAMINE RECEPTOR; PEROSPIRONE; RISPERIDONE; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; MALE; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 70350058705     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2009.6.3.222     Document Type: Article

References (14)

1. Xing Q, Qian X, Li H, Wong S, Wu S, Feng G, et al. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol 2007;10:631-637. (Pubitemid 47517516)
2. Wang L, Yu L, He G, Zhang J, Zhang AP, Du J, et al. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci Lett 2007;414:1-4. (Pubitemid 46241633)
3. Xuan J, Zhao X, He G, Yu L, Wang L, Tang W, et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology 2008;22:305-311. (Pubitemid 350243359)
4. Dolzan V, Plesnicar BK, Serretti A, Mandelli L, Zalar B, Koprivsek J, et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet 2007;144B:809-815. (Pubitemid 47417211)
5. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008;40:827-834. (Pubitemid 351913655)
6. Hirose A, Kato T, Ohno Y, Shimizu H, Tanaka H, Nakamura M, et al. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions. Jpn J Pharmacol 1990;53:321-329. (Pubitemid 20207768)
7. Sakamoto H, Matsumoto K, Ohno Y, Nakamura M. Anxiolytic-like effects of perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic agent. Pharmacol Biochem Behav 1998;60:873-878. (Pubitemid 28349948)
8. Shiwa T, Amano T, Matsubayashi H, Seki T, Sasa M, Sakai N. Perospirone, a novel antipsychotic agent, hyperpolarizes rat dorsal raphe neurons via 5-HT1A receptor. J Pharmacol Sci 2003;93:114-117. (Pubitemid 37254275)
9. Togo T, Iseki E, Shoji M, Oyama I, Kase A, Uchikado H, et al. Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone. J Pharmacol Sci 2003;91:259-262. (Pubitemid 36575585)
10. Wang E, Ding YC, Flodman P, Kidd JR, Kidd KK, Grady DL, et al. The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus. Am J Hum Genet 2004;74:931-944. (Pubitemid 38568966)
11. D'Souza UM, Russ C, Tahir E, Mill J, McGuffin P, Asherson PJ, et al. Functional effects of a tandem duplication polymorphism in the 5′flanking region of the DRD4 gene. Biol Psychiatry 2004;56:691-697. (Pubitemid 39446852)
12. Okuyama Y, Ishiguro H, Toru M, Arinami T. A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem Biophys Res Commun 1999;258:292-295. (Pubitemid 29287044)
13. Stefanis NC, Bresnick JN, Kerwin RW, Schofield WN, McAllister G. Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain. Brain Res Mol Brain Res 1998;53:112-119. (Pubitemid 28085447)
14. Lidow MS, Goldman-Rakic PS. Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther 1997;283:939-946.